IOVANCE BIOTHERAPEUTICS, INC. 8-K

What Happened

• Iovance Biotherapeutics, Inc. announced and furnished a press release on May 7, 2026 reporting its financial results for the quarter ended March 31, 2026 and provided an update on recent developments. The press release was filed as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: May 7, 2026; Quarter covered: Q1 2026 (ended March 31, 2026).
• The company issued a press release with the quarterly results and business update (Exhibit 99.1).
• The Form 8-K disclosure was submitted under Item 2.02 (Results of Operations and Financial Condition).

Why It Matters

• Quarterly results and company updates give investors current information on earnings, revenue trends, cash position, and program progress—key inputs for evaluating biotech firms like Iovance.
• Even though this Form 8-K furnishes the press release rather than detailed SEC financial statements in the filing text, investors should review the attached press release (Exhibit 99.1) and the company’s quarterly report (10-Q) for full figures and context before making decisions.